Peer-reviewed veterinary case report
Dog mast cell tumors grades II and III tested for response to ATRA
By Pinello, K C et al.·Published in Veterinary research communications·2009·Department of Pathology, Brazil·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: In vitro chemosensitivity of canine mast cell tumors grades II and III to all-trans-retinoic acid (ATRA).
- Species:
- dog
Plain-English summary
A study looked at how well all-trans retinoic acid (ATRA) could treat mast cell tumors (MCT) in dogs, which are common skin tumors. The researchers found that when they treated cultured mast cells from dogs with grades II and III tumors with ATRA, the cells showed significant death within 24 to 48 hours, especially at a concentration of 10(-4) M. This suggests that ATRA could be a promising option for treating these types of tumors in dogs. However, more research is needed to confirm its effectiveness in actual patients.
People also search for: dog mast cell tumor treatment · ATRA for dog cancer · canine skin tumor therapy
Abstract
Mast cell tumor (MCT) is one of the most prevalent neoplasms that affect the skin and soft tissue of dogs. Because mast cell tumors present a great variety of clinical appearance and behavior, their treatment becomes a challenge. While retinoids are well recognized as promising antitumor agents, there have been only a few reports about retinoids' effect on canine cancers. The aim of this study was to investigate the chemosensitivity of MCT grades II and III to all-trans retinoic acid (ATRA). Immediately after surgical resection, MCT were prepared for primary culture. Samples of MCTs were also fixed in formalin for histopathology and grading according to the classification of Patnaik et al. (Veterinary Pathology 21(5):469-474, 1984). The best results were obtained when neoplastic mast cells were co-cultivated with fibroblasts. Cultured mast cells were, then, treated with concentrations of 10(-4) to 10(-7) M of ATRA, in order to evaluate their chemosensitivity to this retinoid. MTT assay was performed to estimate cell growth and death. The highest level of mast cell chemosensivity was obtained at the dose of 10(-4) M (p < 0,002). MCT of grades II or III were equally susceptible to the treatment with ATRA. Cell death was observed on the first 24 h until 48 h. According to these results, ATRA may be a potential chemotherapeutic agent for the treatment of canine MCT.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19142741/